
## **SUPPLEMENTARY FIGURES**




Supplementary Figure S1: DLC Gene expression comparison between triple-negative and non-triple-negative breast cancers. Statistical analysis was performed to compare DLC1, DLC2 and DLC3 expression in TCGA breast invasive cancer RNA-Seq dataset combined with clinical data. Medians of DLC1, DLC2 and DLC3 mRNA expression of triple-negative breast cancer (TNBC) and non-triple-negative cancer (Other BC) were calculated and the expressions were compared using Mann-Whitney U test. TNBC n = 112. Other BC n = 761.

## f A DLC1 (variant 2) NM\_006904 Chromosome 8: 12990095-12991174 (GRCh37)


## B DLC2α (variant 1) NM 178006 Chromosome 13:33860701-33858962 (GRCh37)

## C DLC3β variant 3 NM\_001142504 Chromosome X:67912911-67914230 (GRCh37)


**Supplementary Figure S2: DLC promoter sequences.** The sequences of predominantly expressed *DLC* genes are used. **A.** *DLC1* variant 2. **B.** *DLC2* alpha, variant 1. **C.** *DLC3* beta, variant 3. The sequences of the first exons are highlighted with capital letters.



**Supplementary Figure S3:** *DLC1* **promoter methylation in LSC, LAD and HCC.** DNA methylation beta values of probes in selected regions were used for means and standard errors calculation. The result shows one of nine of *DLC1* promoter regions in LAD has higher methylation than LSC. Four of nine of *DLC1* promoter regions in LSC has higher methylation than LAD. Eight of nine of *DLC1* promoter regions in LSC and LAD have higher methylation than HCC.



**Supplementary Figure S4: Relationship between DNA methylation and** *DLC1* **expression in cancers.** TCGA DNA methylation beta values from probe cg24819686 and *DLC1* RNA-Seq values are plotted for LSC **A.**, LAD **B.** and HCC **C.** 



Supplementary Figure S5: Combination of *DLC1* down-regulation and *TP53* mutation is related to smoking status in lung adenocarcinoma. A. DLC expression and TP53 mutations in smokers with lung adenocarcinoma from TCGA lung adenocarcinoma patients whose smoking history was known. The graph represents the number and percentage of cases in each smoker category that had both low DLC1 mRNA expression and TP53 mutation. B. Median DLC values of never smokers (n = 32), former smokers (n = 268), and current smokers (n = 49), from Director's Challenge Lung Study cohort. (lung adenocarcinoma), was calculated and compared using Mann-Whitney U test. For DLC1 and DLC3, both never smokers and former smokers have higher expression than current smokers.